Laos Pharma No.2 Cabozantinib 20mg

Product Information

• Product name: Cabozantinib 20mg
• Manufacturer / brand: Laos State Pharmaceutical No.2
• Active ingredient: Cabozantinib
• Current strength: 20mg
• SKU: L2-ITEM-33
• Site category: general medicines, kidney cancer, liver cancer, thyroid cancer

Product Summary

Cabozantinib 20mg is an AISTIKA-listed product supplied by Laos State Pharmaceutical No.2. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Cabozantinib is the active ingredient used for this product page. Public prescribing information for Cabozantinib was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.

Reference Indications

Cabozantinib is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). Cabozantinib is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).

Reference Dosage and Administration

Recommended Dose: 140 mg orally, once daily. Swallow Cabozantinib capsules whole.

With this 20mg product, that corresponds to 7 x 20mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Perforations and Fistulas: Monitor for symptoms. Discontinue Cabozantinib for Grade 4 fistula or perforation. Hemorrhage: Do not administer Cabozantinib if recent history of hemorrhage. Thrombotic Events: Discontinue Cabozantinib for myocardial infarction or serious arterial or venous thromboembolic events. Impaired Wound Healing: Withhold Cabozantinib for at least 3 weeks before elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of Cabozantinib after resolution of wound healing complications has not been established. Hypertension and hypertensive crisis: Monitor blood pressure regularly. Interrupt for hypertension that is not adequately controlled with anti- hypertensive therapy.

Common Adverse Reactions and Monitoring

The most common laboratory abnormalities (≥ 25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia. The data described below reflect a median exposure to Cabozantinib for 204 days. The population exposed to Cabozantinib was 70% male, 90% white, and had a median age of 55 years. The Cabozantinib dose was reduced in 79% of patients receiving Cabozantinib and in 9% of patients receiving placebo. The median number of dosing delays was one in patients receiving Cabozantinib and in no patients receiving placebo.

Drug Interactions and Special Populations

Strong CYP3A4 Inhibitors: Reduce the Cabozantinib dosage. ( 2.2 , 7.1 ) Strong CYP3A4 Inducers: Increase the Cabozantinib dosage. ( 2.2 , 7.2 ) 7.1 Effect of CYP3A4 Inhibitors Administration of a strong CYP3A4 inhibitor, ketoconazole to healthy subjects increased single-dose plasma cabozantinib exposure by 38%. Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) while taking Cabozantinib or reduce the dosage of Cabozantinib if concomitant use with strong CYP3A4 inhibitors cannot be avoided . Avoid ingestion of foods (e.g., grapefruit, grapefruit juice) or nutritional supplements that are known to inhibit cytochrome P450 while taking Cabozantinib.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: COMETRIQ public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.